Rivia builds a data engine for clinical trials, combining TypeScript/React frontend with Python and Java backends on PostgreSQL and AWS. The stack shows a modern, AI-first architecture—GPT-4 integration appears directly in the core tech, not as an afterthought. Hiring is accelerating across engineering and sales from a 11–50 base, with senior roles concentrated in engineering, suggesting the company is scaling the platform's AI and backend capabilities to support growing trial complexity.
Rivia provides a clinical trial intelligence platform designed to help biotechs run global trials more efficiently and de-risk drug development. Founded in 2022 and based in Zurich, the company serves European and US biotech clients with a data engine that centralizes fragmented trial information and surfaces insights earlier in development. The platform includes AI-driven workflows for trial monitoring and data quality assurance, backed by scalable cloud infrastructure. Customers report measurable improvements in therapeutic-potential understanding and trial execution speed.
Rivia uses TypeScript and React for frontend, Java and Python for backend services, PostgreSQL for databases, and AWS with Kubernetes for cloud infrastructure. GPT-4 is integrated into the core platform for AI-driven features.
Rivia is building AI workflows for clinical trial monitoring and data quality assurance, design systems, and scalable backend services. The platform integrates cloud services and ML components to help biotech teams centralize and act on fragmented trial data.
Other companies in the same industry, closest in size